#### **∂** Open Access Full Text Article

#### ORIGINAL RESEARCH

Efficacy and safety of ramosetron versus ondansetron for postoperative nausea and vomiting after general anesthesia: a meta-analysis of randomized clinical trials

Chengjie Gao Bo Li Lufeng Xu Fubin Lv Guimao Cao Huixia Wang Fei Wang Guanghan Wu

Department of Anesthesiology, General Hospital of Jinan Military Command, Jinan, People's Republic of China

Correspondence: Chengjie Gao Department of Anesthesiology, General Hospital of Jinan Military Command, 25 Shifan Road, Jinan, Shandong 25003 I, People's Republic of China Email gaochjmd@yeah.net

submit your manuscript | www.dovepress.com Dovepress

http://dx.doi.org/10.2147/DDDT.S80407

**Background:** Postoperative nausea and vomiting is a common side effect of general anesthesia. In this study, we performed a meta-analysis on the efficacy and safety of ramosetron versus ondansetron in the prevention of postoperative nausea and vomiting using the most recently published randomized controlled clinical studies.

**Methods:** PubMed and EMBASE were searched for randomized controlled clinical trials comparing the efficacy and safety of ramosetron and ondansetron. The meta-analysis was performed using Review Manager version 5.3 (Cochrane Collaboration, Oxford, UK). Dichotomous outcomes are presented as the relative risk (RR) with a 95% confidence interval (CI).

**Results:** A total of 898 patients from nine selected studies were treated with antiemetics after surgery, including 450 patients who received ondansetron 4 mg and 448 patients who received ramosetron 0.3 mg. The meta-analysis showed no statistically significant difference between the two groups with regard to prevention of postoperative nausea (PON) during different time periods in the 48 hours after surgery. When comparing the efficacy of ramosetron and ondansetron in the prevention of postoperative vomiting (POV), at various time intervals in the 24 hours after surgery, ramosetron was significantly more efficient than ondansetron: 0-6 hours (RR 0.46, 95% CI 0.24–0.92; P=0.03), 0-24 hours (RR 0.72, 95% CI 0.52–1.00; P=0.05), and 6-24 hours (RR 0.51, 95% CI 0.31–0.84; P=0.008). At other time periods between 24 and 48 hours after surgery, ramosetron did not show better efficacy than ondansetron. When comparing the safety profiles of ramosetron and ondansetron, fewer side effects were recorded in the ramosetron group (RR 0.65, 95% CI 0.47–0.91; P=0.01).

**Conclusion:** Our meta-analysis demonstrates that ramosetron was more effective than ondansetron in the prevention of early POV (0–24 hours) with fewer recorded side effects. However, our study did not reveal any statistically significant differences in efficacy between ramosetron and ondansetron in the prevention of PON or late POV (at 24–48 hours).

**Keywords:** ramosetron, ondansetron, postoperative nausea and vomiting, general anesthesia, meta-analysis

# Introduction

Postoperative nausea and vomiting (PONV) is a common side effect after general anesthesia, with an incidence of around 30%.<sup>1</sup> Risk factors for PONV are both anesthesiarelated and non-anesthesia-related. Clinical studies show that the anesthesia-related risk factors for PONV are use of volatile anesthetics and postoperative opioid analgesics.<sup>2</sup> However, the mechanism underlying these two primary risk factors is currently not well understood.<sup>3</sup> Non-anesthesia-related risk factors for PONV include female sex,

how to request permission may be found at: http://www.dovepress.com/permissions.php

© 2015 Gao et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on history of PONV or motion sickness, being a non-smoker, and younger age.<sup>2</sup>

Although PONV is not a life-threatening medical complication, failure to control PONV substantially increases the time to discharge, resource utilization of the post-anesthesia care unit, and cost of medical care.<sup>4</sup> Antiemetic drugs used to control PONV include cholinergic receptor antagonists, histamine receptor antagonists, serotonin antagonists, dopamine antagonists, and NK1 antagonists.<sup>3,5</sup> Serotonin type 3 (5-HT3) receptor antagonists are the antiemetic drugs most commonly used in post-anesthesia care. The first line of choice among the 5-HT3 receptor antagonists is ondansetron.<sup>6</sup> However, recent cardiac safety concerns regarding ondansetron limit its use in certain anesthesia settings if a high dose is required.<sup>7</sup> Ramosetron is a newly developed 5-HT3 receptor antagonist which shows more prolonged activity than ondansetron and is very effective in preventing PONV.8-11 To provide an updated evaluation of the effectiveness of ramosetron, we performed a meta-analysis on the efficacy and safety of ramosetron versus ondansetron using the most recently published randomized controlled clinical studies.

# Materials and methods Search strategy, selection criteria, and study quality assessment

We searched the PubMed and EMBASE databases up to November 2014 for relevant clinical studies. Search terms used for PubMed were: ("ramosetron" [Supplementary Concept] OR "ramosetron" [All Fields]) AND ("ondansetron" [MeSH Terms] OR "ondansetron" [All Fields]) AND ("postoperative nausea and vomiting" [MeSH Terms] OR ("postoperative" [All Fields] AND "nausea" [All Fields] AND "vomiting" [All Fields]) OR "postoperative nausea and vomiting" [All Fields] OR "ponv" [All Fields]). Search terms used for EMBASE were: postoperative vomiting/or postoperative complication/or ondansetron/or ramosetron/ or nausea/or vomiting/AND randomized clinical trial ramosetron.ti,ab./AND \*ondansetron/and \*ramosetron/. Clinical studies in the reference lists of recent published trials with retrievable full text were also searched. Randomized controlled clinical trials comparing the efficacy and safety profiles of ramosetron and ondansetron were selected by title and abstract screening followed by full text retrieval. Reviews, conference abstracts, and non-English language articles were excluded. Only studies using standard doses of ramosetron (4 mg) and ondansetron (0.3 mg)without dexamethasone as an adjunct were selected for meta-analysis. Two authors (CG, BL) independently

performed the search and selected the relevant studies. Any discrepancy in the final selection was resolved by group discussion between all authors. The quality of the selected studies was assessed using the Jadad scoring system, which evaluates the randomization strategy, controls included, and description of withdrawal and dropouts in the study period. A study with a Jadad score  $\geq$ 3 is regarded as being of high quality.<sup>12</sup>

# Data extraction, outcomes, and statistical analysis

Data extracted from each selected study were: author, year of publication, study design, number of patients analyzed, type of anesthesia, type of surgery, treatment regimen for ramosetron and ondansetron, and primary and secondary outcomes. The primary outcome was the incidence of postoperative nausea (PON) and postoperative vomiting (POV). The secondary outcome was side effects following administration of ramosetron or ondansetron, including headache, dizziness, and drowsiness. The meta-analysis was performed using Review Manager version 5.3 (Cochrane Collaboration, Oxford, UK). Dichotomous outcomes are presented as the relative risk (RR) with a 95% confidence interval (CI). The presence of heterogeneity was evaluated with the  $I^2$  statistic. P < 0.05 was considered to be statistically significant and a random-effects model was used for the meta-analysis. Fixedeffects model was used if heterogeneity was not significant across selected studies.

# Results

# Study identification and characteristics

We identified a total of 68 records using our search strategy. Studies published by Yoshitaka Fujii were excluded due to concerns raised by other investigators.<sup>10,11</sup> After initial title and abstract screening and full text retrieval, only nine studies met our selection criteria and were eligible for meta-analysis<sup>13–21</sup> (Figure 1). The characteristics of the selected studies are summarized in Table 1. Most of these studies were very well designed randomized controlled clinical trials, with a Jadad score of 4 or 5.

## Outcomes

#### Primary outcomes: PON and POV

A total of 898 patients from nine selected studies were treated with antiemetics after surgery, including 450 patients who received ondansetron 4 mg and 448 patients who received ramosetron 0.3 mg. PON and POV events were recorded at different time intervals in the nine studies. Meta-analysis of




Figure I Flow diagram of study selection.

results showed no statistically significant difference in PON between patients receiving ramosetron and those receiving ondansetron in the different time periods in the 24 hours after surgery: 0-2 hours (RR 0.54, 95% CI 0.23–1.25; *P*=0.15), 0-6 hours (RR 0.84, 95% CI 0.44–1.63; *P*=0.61), 0-24 hours (RR 0.89, 95% CI 0.63–1.27; *P*=0.53), 2–24 hours (RR 0.47, 95% CI 0.15–1.49; *P*=0.2), or 6–24 hours (RR 0.88, 95% CI 0.58–1.35; *P*=0.56). However, ramosetron had a tendency to be more effective than ondansetron during the 24–48-hour time period after surgery, but this effect did not reach statistical significance (RR 0.60, 95% CI 0.36–1.01; *P*=0.06), (Figure 2). Ramosetron had different effects versus ondansetron on POV

as compared with PON. During some of the time periods in the 24 hours after surgery, ramosetron showed higher efficacy than ondansetron for POV: 0-6 hours (RR 0.46, 95% CI 0.24-0.92; P=0.03), 0-24 hours (RR 0.72, 95% CI 0.52-1.00; P=0.05) and 6-24 hours (RR 0.51, 95% CI 0.31-0.84; P=0.008). At other time periods, including the 24-48 hours after surgery, ramosetron was no more effective than ondansetron in prevention of POV: 0-2 hours (RR 0.67, 95% CI 0.11-4.00; P=0.66), 2-6 hours (RR 0.55, 95% CI 0.21-1.47; P=0.24), 2-24 hours (RR 0.37, 95% CI 0.10-1.35; P=0.13), and 24-48 hours (RR 0.51, 95% CI 0.17-1.51; P=0.22, Figure 3). We did not include the study by Banerjee et al<sup>22</sup> in our meta-analysis because these authors did not provide detailed PON and POV outcomes. However, their results showed that preoperative administration of a single intravenous dose of ramosetron 0.3 mg was more effective than a single intravenous dose of ondansetron 4 mg in reducing the incidence of PONV in general in the 18 hours after surgery.

# Secondary outcome: side effects of ramosetron and ondansetron

Four studies presented full data on side effects (headache, dizziness, drowsiness) after treatment with ramosetron or ondansetron in the 48 hours after surgery.<sup>13,15,17,21</sup> Ramosetron had fewer recorded side effects than ondansetron (RR 0.65, 95% CI 0.47–0.91; *P*=0.01, Figure 4). Other studies did not present detailed data on side effects, but mentioned in their results that there was no statistically significant difference between ramosetron and ondansetron.

## Publication bias

The potential publication bias of the selected studies was assessed using a Begg's funnel plot. No publication bias was detected for the time periods of 0–24 hours, 6–24 hours, and 24–48 hours. There was some publication bias concerning data for other time periods after surgery (Figure 5).

# Discussion

The previous positive clinical results published by Fujii et al on the efficacy of ramosetron have been criticized and reevaluated.<sup>10,11</sup> The most recent meta-analysis by Mihara et al showed no significant difference between ramosetron and ondansetron in the prevention of PON.<sup>10</sup> They found ramosetron was much more effective in the prevention of POV than ondansetron. Consistent with their results for PON, our meta-analysis showed no statistically significant difference between ramosetron and ondansetron in the prevention of PON during any of the time periods in the

Reference	Study design	Type of anesthesia	Type of surgery	Treatment regimen	Outcomes	Patients analyzed (n)	Jadad score
Ryu et al <sup>13</sup>	RCT, DB	Propofol 4 µg/mL + remifentanil 3–4 ng/mL	Craniotomy	Ondansetron 4 mg (group A), ondansetron 8 mg (group B), or	PONV (0–48 hours); drowsiness, dizziness,	127	2
Kaja et al <sup>14</sup>	RCT	Propofol 2 mg/kg + fentanyl 2 μg/kg + N <sub>2</sub> O	Abdominal surgery	ramosetron 0.3 mg (group C); IV Ramosetron 0.3 mg; ondansetron 4 mg: IV	and QTc prolongation PONV (0–24 hours); headache, dizziness,	60	m
Lee et al <sup>is</sup>	RCT, DB	1.0–4.0 vol% sevoflurane and 50%	Abdominal hysterectomy	Ramosetron 0.3 mg; ondansetron 4 mg; IV	drowsiness, EPS PONV (0–48 hours); headache, dizziness	120	4
Choi et al <sup>16</sup>	RCT, DB	N <sub>2</sub> O in oxygen Propofol and remifentanil	Cardiac surgery	Ramosetron 0.3 mg +0.6 mg in PCA; ondansetron 4 mg +12 mg in PCA: IV	PONV (0–48 hours); headache, dizziness, diarrhea, episodes of	279	Ŋ
Ansari et al <sup>17</sup>	RCT, DB	Sevoflurane + $N_2O$	Laparoscopic cholecystectomy	Ramosetron 0.3 mg; ondansetron 4 mg; IV	arrhythmias PONV (0–48 hours); headache, dizziness, dyspepsia, weakness,	l 30 (female)	2
Hahm et al <sup>18</sup>	RCT, DB	Propofol	Total knee replacement	Ramosetron 0.3 mg; ondansetron	flushing PONV (0–48 hours)	84 (female)	4
Ryu et al' <sup>9</sup>	RCT, DB	0.2–2.0 pg/mL Desflurane 3%–6% + remifentanil 2–3 ng/mL	Laparoscopic cholecystectomy	A mg, 19 Ramosetron 0.3 mg; ondansetron 4 or 8 mg; IV	PONV (0-48 hours); headache, dizziness,	120	S
Kim et al <sup>20</sup>	RCT, DB	Sevoflurane 0.5%–5% + N.O	Gynecological surgery	Ramosetron 0.3 mg; ondansetron 8 mg; IV	PONV (0-24 hours); headache, dizziness	162	ъ
Choi et al <sup>21</sup>	RCT, DB	Propofol 1.5–2.5 mg/kg and remifentanil 0.5–1 g/kg	Lumbar spine surgery	Ramosetron 0.3 mg; ondansetron 4 mg +12 mg in PCA; IV	PONV (0–48 hours); headache, dizziness, drowsiness	94 (female)	'n

2346

submit your manuscript | www.dovepress.com

Dovepress

subgroup				etron (4 mg)	Weight	Risk ratio M–H,	Year	Risk ratio M–H,
	Events	Total	Events	Total		random, 95% Cl		random, 95% Cl
1.1.1 0–24 hours								
Ryu et al <sup>19</sup>	8	40	17	40	35.1%	0.47 (0.23, 0.96)	2010	<b></b>
Hahm et al <sup>18</sup>	1	42	7	42	12.3%	0.14 (0.02, 1.11)	2010 -	
Lee et al <sup>15</sup>	13	60	10	60	34.4%	1.30 (0.62, 2.73)	2011	
Ryu et al <sup>13</sup>	2	42	6	41	18.2%	0.33 (0.07, 1.52)	2014	
Subtotal (95% CI)		184		183	100%	0.54 (0.23, 1.25)		
Total events Heterogeneity: $\tau^2=0.3$			40 0.07); /²=58	%				
Test for overall effect	2-1.45 (/	0.15)						
1.1.2 0–6 hours Choi et al <sup>21</sup>	24	47	22	47	26.0%	1 25 (0.04, 1.02)	2000	
Kim et al <sup>20</sup>	31 18	47 54	23 19	47 54	36.0% 32.1%	1.35 (0.94, 1.93) 0.95 (0.56, 1.60)	2008 2009	
Hahm et al <sup>18</sup>	12	42	27	42	31.9%	0.44 (0.26, 0.75)	2009	- <b>-</b> -1
Subtotal (95% CI)		143		143	100%	0.84 (0.44, 1.63)	2010	
otal events	61		69					
Heterogeneity: τ <sup>2</sup> =0.2 Test for overall effect			0.003); /2=	83%				
.1.4 0–24 hours								
Kim et al <sup>20</sup>	27	54	24	54	22.5%	1.13 (0.75, 1.68)	2009	
Choi et al <sup>16</sup>	27	68	26	71	21.7%	1.08 (0.71, 1.66)	2010	- <b>-</b> -
Ansari et al <sup>17</sup>	14	65	19	65	16.6%	0.74 (0.40, 1.34)	2010	- <b>•</b> +
Ryu et al <sup>19</sup>	12	40	27	40	18.8%	0.44 (0.26, 0.75)	2010	
ee et al <sup>15</sup>	25	60	20	60	20.4%	1.25 (0.78, 1.99)	2011	
Subtotal (95% CI)	105	287	110	290	100%	0.89 (0.63, 1.27)		
otal events	105		116					
Heterogeneity: $\tau^2=0.7$ Test for overall effects			0.02); /2=6	5%				
.1.5 2–24 hours								
Ryu et al <sup>19</sup>	4	40	10	40	32.0%	0.40 (0.14, 1.17)	2010	
	•							-
ee et al15	12	60	10	60	37.1%	1.20 (0.56, 2.56)	2011	•
.ee et al <sup>15</sup> Ryu et al <sup>13</sup>	•	60 41		60 41	37.1% 30.8%	1.20 (0.56, 2.56) 0.18 (0.06, 0.56)		
Lee et al <sup>15</sup> Ryu et al <sup>13</sup> Subtotal (95% Cl)	12 3	60	10 17	60	37.1%	1.20 (0.56, 2.56)	2011	
ee et al <sup>15</sup> Ryu et al <sup>13</sup> Subtotal (95% CI) Fotal events	12 3 19	60 41 <b>141</b>	10 17 37	60 41 <b>141</b>	37.1% 30.8%	1.20 (0.56, 2.56) 0.18 (0.06, 0.56)	2011	
Lee et al <sup>15</sup> Ryu et al <sup>13</sup> Subtotal (95% CI) Total events Heterogeneity: $\tau^2=0.8$ Fest for overall effect	12 3 19 80; χ <sup>2</sup> =8.3	60 41 <b>141</b> 3, <i>df=</i> 2 ( <i>P=</i> 0	10 17 37	60 41 <b>141</b>	37.1% 30.8%	1.20 (0.56, 2.56) 0.18 (0.06, 0.56)	2011	
Lee et al <sup>15</sup> Ryu et al <sup>13</sup> Subtotal (95% CI) Total events Heterogeneity: $r^2=0.8$ Test for overall effect I.1.6 6–24 hours	12 3 19 80; χ <sup>2</sup> =8.3 : Ζ=1.28 ( <i>i</i>	60 41 <b>141</b> 3, <i>df</i> =2 ( <i>P</i> =0 <i>P</i> =0.20)	10 17 37 0.02); /²=76	60 41 <b>141</b> %	37.1% 30.8% <b>100%</b>	1.20 (0.56, 2.56) 0.18 (0.06, 0.56) 0.47 (0.15, 1.49)	2011 2014	
ee et al <sup>15</sup> Subtotal (95% CI) Total events leterogeneity: r <sup>2</sup> =0.8 Test for overall effect .1.6 6–24 hours Choi et al <sup>21</sup>	12 3 19 80; $\chi^{2}=8.3$ :: Z=1.28 ( <i>J</i> 25	60 41 <b>141</b> 3, <i>df</i> =2 ( <i>P</i> =0 P=0.20) 47	10 17 37 0.02); /²=76 25	60 41 <b>141</b> % 47	37.1% 30.8% <b>100%</b> 36.1%	1.20 (0.56, 2.56) 0.18 (0.06, 0.56) 0.47 (0.15, 1.49) 1.00 (0.68, 1.46)	2011 2014 2008	
Lee et al <sup>15</sup> Ryu et al <sup>13</sup> Subtotal (95% CI) Total events Heterogeneity: $\tau^2=0.5$ Test for overall effect I.1.6 6–24 hours Choi et al <sup>21</sup> Kim et al <sup>20</sup>	$12 \\ 3 \\ 19 \\ 80; \chi^{2}=8.3 \\ z=1.28 \ (l) \\ 25 \\ 22 \\ 22$	60 41 <b>141</b> 3, <i>df</i> =2 ( <i>P</i> =( <i>P</i> =0.20) 47 54	10 17 37 0.02); /²=76 25 17	60 41 <b>141</b> % 47 54	37.1% 30.8% <b>100%</b> 36.1% 29.4%	1.20 (0.56, 2.56) 0.18 (0.06, 0.56) 0.47 (0.15, 1.49) 1.00 (0.68, 1.46) 1.29 (0.78, 2.15)	2011 2014 2008 2009	
Lee et al <sup>15</sup> Ryu et al <sup>13</sup> Subtotal (95% CI) Subtotal (95% CI) Fotal events Heterogeneity: $\tau^2=0.6$ Test for overall effect I.1.6 6–24 hours Choi et al <sup>21</sup> Choi et al <sup>21</sup> Hahm et al <sup>18</sup>	$\begin{array}{c} 12\\ 3\\ 19\\ 80; \chi^2=8.3\\ \vdots Z=1.28 \ (l)\\ 25\\ 22\\ 16\end{array}$	60 41 <b>141</b> 3, <i>df</i> =2 ( <i>P</i> =( <i>P</i> =0.20) 47 54 42	10 17 37 0.02); / <sup>2</sup> =76 25 17 28	60 41 <b>141</b> % 47 54 42	37.1% 30.8% <b>100%</b> 36.1% 29.4% 32.8%	1.20 (0.56, 2.56) 0.18 (0.06, 0.56) 0.47 (0.15, 1.49) 1.00 (0.68, 1.46) 1.29 (0.76, 2.15) 0.57 (0.37, 0.89)	2011 2014 2008 2009 2010	
Lee et al <sup>15</sup> Ryu et al <sup>13</sup> Subtotal (95% CI) Fotal events Heterogeneity: $r^2=0.6$ Fest for overall effect I.1.6 6–24 hours Choi et al <sup>21</sup> Kim et al <sup>20</sup> Hahm et al <sup>18</sup> Kaja et al <sup>14</sup>	$12 \\ 3 \\ 19 \\ 80; \chi^{2}=8.3 \\ z=1.28 \ (l) \\ 25 \\ 22 \\ 22$	60 41 <b>141</b> 3, <i>df</i> =2 ( <i>P</i> =( <i>P</i> =0.20) 47 54 42 30	10 17 37 0.02); /²=76 25 17	60 41 <b>141</b> % 47 54	37.1% 30.8% <b>100%</b> 36.1% 29.4% 32.8% 1.7%	1.20 (0.56, 2.56) 0.18 (0.06, 0.56) 0.47 (0.15, 1.49) 1.00 (0.68, 1.46) 1.29 (0.78, 2.15) 0.57 (0.37, 0.89) 0.33 (0.01, 7.87)	2011 2014 2008 2009	
Lee et al <sup>15</sup> Ryu et al <sup>13</sup> Subtotal (95% CI) Total events Heterogeneity: $r^2=0.6$ Test for overall effect 1.1.6 6–24 hours Choi et al <sup>21</sup> Kim et al <sup>20</sup> Hahm et al <sup>18</sup> Kaja et al <sup>14</sup> Subtotal (95% CI)	12 3 19 80; χ <sup>2</sup> =8.3 :: Ζ=1.28 (μ 25 22 16 0	60 41 <b>141</b> 3, <i>df</i> =2 ( <i>P</i> =( <i>P</i> =0.20) 47 54 42	10 17 37 0.02); /²=76 25 17 28 1	60 41 <b>141</b> % 47 54 42 30	37.1% 30.8% <b>100%</b> 36.1% 29.4% 32.8%	1.20 (0.56, 2.56) 0.18 (0.06, 0.56) 0.47 (0.15, 1.49) 1.00 (0.68, 1.46) 1.29 (0.76, 2.15) 0.57 (0.37, 0.89)	2011 2014 2008 2009 2010	
ee et al <sup>15</sup> Xyu et al <sup>13</sup> Subtotal (95% CI) Total events Heterogeneity: $\tau^2=0.6$ Test for overall effect: 1.1.6 –24 hours Choi et al <sup>21</sup> Choi et al <sup>21</sup> Choi et al <sup>21</sup> Gim et al <sup>18</sup> Caja et al <sup>14</sup> Subtotal (95% CI) Total events Heterogeneity: $\tau^2=0.6$	12 3 19 80; $\chi^2=8.3$ : $z=1.28$ ( $\mu$ 25 22 16 0 63 009; $\chi^2=6.7$	60 41 <b>141</b> 3, <i>df</i> =2 ( <i>P</i> =( <i>P</i> =0.20) 47 54 42 30 <b>173</b> 0, <i>df</i> =3 ( <i>P</i> =(	10 17 37 0.02); /²=76 25 17 28 1 1 71	60 41 <b>141</b> % 47 54 42 30 <b>173</b>	37.1% 30.8% <b>100%</b> 36.1% 29.4% 32.8% 1.7%	1.20 (0.56, 2.56) 0.18 (0.06, 0.56) 0.47 (0.15, 1.49) 1.00 (0.68, 1.46) 1.29 (0.78, 2.15) 0.57 (0.37, 0.89) 0.33 (0.01, 7.87)	2011 2014 2008 2009 2010	
Lee et al <sup>15</sup> Ryu et al <sup>13</sup> Subtotal (95% CI) Total events Heterogeneity: $\tau^2=0.6$ Test for overall effect: I.1.6 6–24 hours Choi et al <sup>21</sup> Choi et al <sup>21</sup> Choi et al <sup>21</sup> Hahm et al <sup>18</sup> Subtotal (95% CI) Total events Heterogeneity: $\tau^2=0.6$ Test for overall effect:	12 3 19 80; $\chi^2=8.3$ : $z=1.28$ ( $\mu$ 25 22 16 0 63 009; $\chi^2=6.7$	60 41 <b>141</b> 3, <i>df</i> =2 ( <i>P</i> =( <i>P</i> =0.20) 47 54 42 30 <b>173</b> 0, <i>df</i> =3 ( <i>P</i> =(	10 17 37 0.02); /²=76 25 17 28 1 1 71	60 41 <b>141</b> % 47 54 42 30 <b>173</b>	37.1% 30.8% <b>100%</b> 36.1% 29.4% 32.8% 1.7%	1.20 (0.56, 2.56) 0.18 (0.06, 0.56) 0.47 (0.15, 1.49) 1.00 (0.68, 1.46) 1.29 (0.78, 2.15) 0.57 (0.37, 0.89) 0.33 (0.01, 7.87)	2011 2014 2008 2009 2010	
Lee et al <sup>15</sup> Ryu et al <sup>13</sup> Subtotal (95% CI) Fotal events Heterogeneity: $r^2=0.6$ Fest for overall effect I.1.6 6–24 hours Choi et al <sup>21</sup> Choi et al <sup>20</sup> Hahm et al <sup>18</sup> Subtotal (95% CI) Fotal events Heterogeneity: $r^2=0.0$ Fest for overall effect I.1.7 24–48 hours	12 3 19 80; $\chi^2=8.3$ : $Z=1.28$ ( $i$ 25 22 16 0 63 009; $\chi^2=6.7$ : $Z=0.59$ ( $i$	60 41 <b>141</b> 3, <i>df</i> =2 ( <i>P</i> =( <i>P</i> =0.20) 47 54 42 30 <b>173</b> 0, <i>df</i> =3 ( <i>P</i> =(	10 17 37 0.02); /²=76 25 17 28 1 1 71	60 41 141 % 47 54 42 30 173	37.1% 30.8% 100% 36.1% 29.4% 32.8% 1.7% 100%	1.20 (0.56, 2.56) 0.18 (0.06, 0.56) 0.47 (0.15, 1.49) 1.00 (0.68, 1.46) 1.29 (0.78, 2.15) 0.57 (0.37, 0.89) 0.33 (0.01, 7.87) 0.88 (0.58, 1.35)	2011 2014 2008 2009 2010 2014 —	
Lee et al <sup>15</sup> Ryu et al <sup>13</sup> Subtotal (95% CI) Solat events Heterogeneity: $r^2=0.6$ Test for overall effect I.1.6 6–24 hours Choi et al <sup>21</sup> Kim et al <sup>20</sup> Hahm et al <sup>18</sup> Kaja et al <sup>14</sup> Subtotal (95% CI) Total events Heterogeneity: $r^2=0.6$ Test for overall effect I.1.7 24–48 hours Choi et al <sup>21</sup>	12 3 19 80; $\chi^2=8.3$ : $z=1.28$ ( $\mu$ 25 22 16 0 63 009; $\chi^2=6.7$	60 41 141 3, df=2 (P=( P=0.20) 47 54 42 30 173 0, df=3 (P=( P=0.56)	10 17 37 0.02); <i>I</i> <sup>2</sup> =76 25 17 28 1 71 0.08); <i>I</i> <sup>2</sup> =55	60 41 <b>141</b> % 47 54 42 30 <b>173</b>	37.1% 30.8% <b>100%</b> 36.1% 29.4% 32.8% 1.7%	1.20 (0.56, 2.56) 0.18 (0.06, 0.56) 0.47 (0.15, 1.49) 1.00 (0.68, 1.46) 1.29 (0.78, 2.15) 0.57 (0.37, 0.89) 0.33 (0.01, 7.87)	2011 2014 2008 2009 2010	
ee et al <sup>15</sup> Syu et al <sup>13</sup> Subtotal (95% CI) otal events leterogeneity: $r^2=0.6$ rest for overall effect <b>.1.6 6–24 hours</b> Choi et al <sup>21</sup> Gim et al <sup>20</sup> lahm et al <sup>18</sup> Subtotal (95% CI) otal events leterogeneity: $r^2=0.6$ rest for overall effect <b>.1.7 24–48 hours</b> Choi et al <sup>21</sup> Syu et al <sup>19</sup>	12 3 19 80; $\chi^2=8.3$ :: $Z=1.28$ ( $\mu$ 25 22 16 0 63 009; $\chi^2=6.7$ :: $Z=0.59$ ( $\mu$ 12	60 41 141 3, df=2 (P=( P=0.20) 47 54 42 30 173 0, df=3 (P=( P=0.56) 47	10 17 37 0.02); I <sup>2</sup> =76 25 17 28 1 71 0.08); I <sup>2</sup> =55 17	60 41 141 % 47 54 42 30 173 %	37.1% 30.8% 100% 36.1% 29.4% 32.8% 1.7% 100%	1.20 (0.56, 2.56) 0.18 (0.06, 0.56) 0.47 (0.15, 1.49) 1.00 (0.68, 1.46) 1.29 (0.78, 2.15) 0.57 (0.37, 0.89) 0.33 (0.01, 7.87) 0.88 (0.58, 1.35) 0.71 (0.38, 1.31)	2011 2014 2008 2009 2010 2014 — 2008	
Lee et al <sup>15</sup> Ryu et al <sup>13</sup> Subtotal (95% CI) Sotal events Heterogeneity: $r^2=0.6$ Test for overall effect I.1.6 6–24 hours Choi et al <sup>21</sup> Kim et al <sup>20</sup> Hahm et al <sup>18</sup> Subtotal (95% CI) Total events Heterogeneity: $r^2=0.6$ Test for overall effect I.1.7 24–48 hours Choi et al <sup>21</sup> Ryu et al <sup>19</sup> Nasari et al <sup>17</sup> Hahm et al <sup>18</sup>	12 3 19 80; $\chi^2=8.3$ :: $Z=1.28$ ( $\mu$ 25 22 16 0 63 009; $\chi^2=6.7$ : $Z=0.59$ ( $\mu$ 12 0 7 21	60 41 141 3, df=2 (P=( P=0.20) 47 54 42 30 173 0, df=3 (P=( P=0.56) 47 40	10 17 37 0.02); l <sup>2</sup> =76 25 17 28 1 71 0.08); l <sup>2</sup> =55 17 2 15 29	60 41 141 % 47 54 42 30 173 % 47 40 65 42	37.1% 30.8% 100% 36.1% 29.4% 32.8% 1.7% 100% 18.9% 2.7% 15.6% 22.9%	1.20 (0.56, 2.56) 0.18 (0.06, 0.56) 0.47 (0.15, 1.49) 1.00 (0.68, 1.46) 1.29 (0.78, 2.15) 0.57 (0.37, 0.89) 0.33 (0.01, 7.87) 0.88 (0.58, 1.35) 0.71 (0.38, 1.31) 0.20 (0.01, 4.04)	2011 2014 2008 2009 2010 2014 — 2008 2010 ↓	
Lee et al <sup>15</sup> Ryu et al <sup>13</sup> Subtotal (95% CI) Sotal events Heterogeneity: $r^2=0.6$ Fest for overall effect: I.1.6 6–24 hours Choi et al <sup>21</sup> Kim et al <sup>20</sup> Hahm et al <sup>18</sup> Kaja et al <sup>14</sup> Subtotal (95% CI) Fotal events Heterogeneity: $r^2=0.6$ Fest for overall effect I.1.7 24–48 hours Choi et al <sup>21</sup> Ryu et al <sup>19</sup> Ansari et al <sup>17</sup> Hahm et al <sup>18</sup> Choi et al <sup>16</sup>	12 3 19 80; $\chi^2=8.3$ : $Z=1.28$ ( $\mu^2$ 25 22 16 0 63 009; $\chi^2=6.7$ : $Z=0.59$ ( $\mu^2$ 12 0 7 21 29	$\begin{array}{c} 60\\ 41\\ 141\\ \end{array}$	10 17 37 0.02); I <sup>2</sup> =76 25 17 28 1 71 0.08); I <sup>2</sup> =55 17 2 15 29 20	60 41 141 % 47 54 42 30 173 % 47 40 65 42 71	37.1% 30.8% 100% 36.1% 29.4% 32.8% 32.8% 1.7% 100% 18.9% 2.7% 15.6% 22.9% 21.5%	1.20 (0.56, 2.56) 0.18 (0.06, 0.56) 0.47 (0.15, 1.49) 1.00 (0.68, 1.46) 1.29 (0.78, 2.15) 0.57 (0.37, 0.89) 0.33 (0.01, 7.87) 0.88 (0.58, 1.35) 0.71 (0.38, 1.31) 0.20 (0.01, 4.04) 0.47 (0.20, 1.07) 0.72 (0.50, 1.04) 1.51 (0.55, 2.40)	2011 2014 2008 2009 2010 2014 2008 2010 2010 2010	
Lee et al <sup>15</sup> Ryu et al <sup>13</sup> Subtotal (95% CI) Total events Heterogeneity: $r^2=0.6$ Test for overall effect 1.1.6 6–24 hours Choi et al <sup>21</sup> Hahm et al <sup>18</sup> Kaja et al <sup>14</sup> Subtotal (95% CI) Total events Heterogeneity: $r^2=0.6$ Test for overall effect 1.1.7 24–48 hours Choi et al <sup>21</sup> Ansari et al <sup>19</sup> Ansari et al <sup>19</sup> Choi et al <sup>21</sup> Choi et al <sup>21</sup> Choi et al <sup>21</sup> Choi et al <sup>21</sup> Choi et al <sup>15</sup>	12 3 19 80; $\chi^2=8.3$ : $Z=1.28$ ( $i$ 25 22 16 0 63 009; $\chi^2=6.7$ : $Z=0.59$ ( $i$ 12 0 7 21 29 1	$\begin{array}{c} 60\\ 41\\ 141\\ 3, df=2 \ (P=0.20)\\ 47\\ 54\\ 42\\ 30\\ 173\\ 0, df=3 \ (P=0.56)\\ 47\\ 40\\ 65\\ 42\\ 68\\ 60\\ \end{array}$	10 17 37 0.02); <i>J</i> <sup>2</sup> =76 25 17 28 1 71 0.08); <i>J</i> <sup>2</sup> =55 17 2 15 29 20 8	60 41 141 % 47 54 42 30 173 % 47 40 65 42 71 60	37.1% 30.8% 100% 36.1% 29.4% 32.8% 1.7% 100% 18.9% 2.7% 15.6% 22.9% 21.5%	1.20 (0.56, 2.56) 0.18 (0.06, 0.56) 0.47 (0.15, 1.49) 1.00 (0.68, 1.46) 1.29 (0.78, 2.15) 0.57 (0.37, 0.89) 0.33 (0.01, 7.87) 0.88 (0.58, 1.35) 0.71 (0.38, 1.31) 0.20 (0.01, 4.04) 0.47 (0.20, 1.07) 0.72 (0.50, 1.04) 1.51 (0.55, 2.40) 0.13 (0.02, 0.97)	2011 2014 2008 2009 2010 2010 2010 2010 2010 2010 2010	
Lée et al <sup>15</sup> Ryu et al <sup>13</sup> <b>Subtotal (95% CI)</b> Total events Heterogeneity: $r^2=0.6$ Test for overall effect <b>1.1.6 6–24 hours</b> Choi et al <sup>21</sup> Kim et al <sup>20</sup> Hahm et al <sup>18</sup> <b>Subtotal (95% CI)</b> Total events Heterogeneity: $r^2=0.0$ Test for overall effect <b>1.1.7 24–48 hours</b> Choi et al <sup>21</sup> Ryu et al <sup>19</sup> Ansari et al <sup>17</sup> Hahm et al <sup>18</sup> Choi et al <sup>16</sup> Lee et al <sup>15</sup> Ryu et al <sup>13</sup>	12 3 19 80; $\chi^2=8.3$ : $Z=1.28$ ( $\mu^2$ 25 22 16 0 63 009; $\chi^2=6.7$ : $Z=0.59$ ( $\mu^2$ 12 0 7 21 29	$\begin{array}{c} 60\\ 41\\ 141\\ \end{array}\\ 3, df=2 (P=0)\\ P=0.20)\\ 47\\ 54\\ 42\\ 30\\ 173\\ \end{array}\\ 0, df=3 (P=0)\\ P=0.56)\\ 47\\ 40\\ 65\\ 42\\ 68\\ 60\\ 42\\ \end{array}$	10 17 37 0.02); I <sup>2</sup> =76 25 17 28 1 71 0.08); I <sup>2</sup> =55 17 2 15 29 20	60 41 141 % 47 54 42 30 173 % 47 40 65 42 71 60 41	37.1% 30.8% 100% 36.1% 32.8% 1.7% 100% 18.9% 2.7% 15.6% 22.9% 21.5% 5.2% 13.1%	1.20 (0.56, 2.56) 0.18 (0.06, 0.56) 0.47 (0.15, 1.49) 1.00 (0.68, 1.46) 1.29 (0.78, 2.15) 0.57 (0.37, 0.89) 0.33 (0.01, 7.87) 0.88 (0.58, 1.35) 0.71 (0.38, 1.31) 0.20 (0.01, 4.04) 0.47 (0.20, 1.07) 0.72 (0.50, 1.04) 1.51 (0.95, 2.40) 0.13 (0.02, 0.97) 0.24 (0.09, 0.67)	2011 2014 2008 2009 2010 2014 2008 2010 2010 2010	
Lee et al <sup>15</sup> Ryu et al <sup>13</sup> <b>Subtotal (95% CI)</b> Total events Heterogeneity: $r^2=0.6$ Test for overall effect <b>1.1.6 6–24 hours</b> Choi et al <sup>21</sup> Kim et al <sup>20</sup> Hahm et al <sup>18</sup> Kaja et al <sup>14</sup> <b>Subtotal (95% CI)</b> Total events Heterogeneity: $r^2=0.0$ Test for overall effect <b>1.1.7 24–48 hours</b> Choi et al <sup>21</sup> Ryu et al <sup>19</sup> Ansari et al <sup>17</sup> Hahm et al <sup>18</sup> Choi et al <sup>16</sup> Lee et al <sup>15</sup> Ryu et al <sup>15</sup> <b>Subtotal (95% CI)</b>	12 3 19 80; $\chi^2=8.3$ :: $Z=1.28$ ( $\mu$ 25 22 16 0 63 009; $\chi^2=6.7$ :: $Z=0.59$ ( $\mu$ 12 0 7 21 29 1 4	$\begin{array}{c} 60\\ 41\\ 141\\ 3, df=2 \ (P=0.20)\\ 47\\ 54\\ 42\\ 30\\ 173\\ 0, df=3 \ (P=0.56)\\ 47\\ 40\\ 65\\ 42\\ 68\\ 60\\ \end{array}$	10 17 37 0.02); l <sup>2</sup> =76 25 17 28 1 71 0.08); l <sup>2</sup> =55 17 2 17 2 15 29 20 8 16	60 41 141 % 47 54 42 30 173 % 47 40 65 42 71 60	37.1% 30.8% 100% 36.1% 29.4% 32.8% 1.7% 100% 18.9% 2.7% 15.6% 22.9% 21.5%	1.20 (0.56, 2.56) 0.18 (0.06, 0.56) 0.47 (0.15, 1.49) 1.00 (0.68, 1.46) 1.29 (0.78, 2.15) 0.57 (0.37, 0.89) 0.33 (0.01, 7.87) 0.88 (0.58, 1.35) 0.71 (0.38, 1.31) 0.20 (0.01, 4.04) 0.47 (0.20, 1.07) 0.72 (0.50, 1.04) 1.51 (0.55, 2.40) 0.13 (0.02, 0.97)	2011 2014 2008 2009 2010 2010 2010 2010 2010 2010 2010	
Nu et al. <sup>15</sup> Ryu et al. <sup>15</sup> Ryu et al. <sup>15</sup> Ryu et al. <sup>13</sup> <b>Subtotal (95% CI)</b> Total events Heterogeneity: $\tau^2=0.5$ Test for overall effect <b>1.1.6 6–24 hours</b> Choi et al. <sup>21</sup> Kim et al. <sup>20</sup> Hahm et al. <sup>18</sup> <b>Subtotal (95% CI)</b> Total events Heterogeneity: $\tau^2=0.5$ Choi et al. <sup>21</sup> Ryu et al. <sup>19</sup> Ansari et al. <sup>17</sup> Hahm et al. <sup>16</sup> Lee et al. <sup>15</sup> Ryu et al. <sup>13</sup> <b>Subtotal (95% CI)</b> Total events Heterogeneity: $\tau^2=0.5$	12 3 19 80; $\chi^2=8.3$ $\therefore Z=1.28$ ( $\mu$ 25 22 16 0 63 009; $\chi^2=6.7$ $\therefore Z=0.59$ ( $\mu$ 12 0 7 21 29 1 4 74	$\begin{array}{c} 60\\ 41\\ 141\\ \end{array}$	10 17 37 0.02); l <sup>2</sup> =76 25 17 28 1 71 0.08); l <sup>2</sup> =55 17 2 8 10 29 20 8 16 107	60 41 141 % 47 54 42 30 173 % 47 40 65 42 71 60 41 366	37.1% 30.8% 100% 36.1% 32.8% 1.7% 100% 18.9% 2.7% 15.6% 22.9% 21.5% 5.2% 13.1%	1.20 (0.56, 2.56) 0.18 (0.06, 0.56) 0.47 (0.15, 1.49) 1.00 (0.68, 1.46) 1.29 (0.78, 2.15) 0.57 (0.37, 0.89) 0.33 (0.01, 7.87) 0.88 (0.58, 1.35) 0.71 (0.38, 1.31) 0.20 (0.01, 4.04) 0.47 (0.20, 1.07) 0.72 (0.50, 1.04) 1.51 (0.95, 2.40) 0.13 (0.02, 0.97) 0.24 (0.09, 0.67)	2011 2014 2008 2009 2010 2010 2010 2010 2010 2010 2010	
Lee et al <sup>15</sup> Ryu et al <sup>13</sup> Subtotal (95% CI) Total events Heterogeneity: $r^2=0.6$ Total events Heterogeneity: $r^2=0.6$ Total events Hahm et al <sup>10</sup> Kaja et al <sup>14</sup> Subtotal (95% CI) Total events Heterogeneity: $r^2=0.6$ Total events Heterogeneity: $r^2=0.6$ Choi et al <sup>21</sup> Ryu et al <sup>19</sup> Ansari et al <sup>17</sup> Hahm et al <sup>18</sup> Lee et al <sup>15</sup> Ryu et al <sup>13</sup> Subtotal (95% CI) Total events Heterogeneity: $r^2=0.6$	12 3 19 80; $\chi^2=8.3$ : $Z=1.28$ ( $\ell$ 25 22 16 0 63 009; $\chi^2=6.7$ : $Z=0.59$ ( $\ell$ 12 0 7 21 29 1 4 74 27; $\chi^2=19.2$	60 41 141 3, df=2 (P=( P=0.20) 47 54 42 30 173 0, df=3 (P=( P=0.56) 47 40 65 42 68 60 42 364 23, df=6 (P=	10 17 37 0.02); l <sup>2</sup> =76 25 17 28 1 71 0.08); l <sup>2</sup> =55 17 2 8 10 29 20 8 16 107	60 41 141 % 47 54 42 30 173 % 47 40 65 42 71 60 41 366	37.1% 30.8% 100% 36.1% 32.8% 1.7% 100% 18.9% 2.7% 15.6% 22.9% 21.5% 5.2% 13.1%	1.20 (0.56, 2.56) 0.18 (0.06, 0.56) 0.47 (0.15, 1.49) 1.00 (0.68, 1.46) 1.29 (0.78, 2.15) 0.57 (0.37, 0.89) 0.33 (0.01, 7.87) 0.88 (0.58, 1.35) 0.71 (0.38, 1.31) 0.20 (0.01, 4.04) 0.47 (0.20, 1.07) 0.72 (0.50, 1.04) 1.51 (0.95, 2.40) 0.13 (0.02, 0.97) 0.24 (0.09, 0.67)	2011 2014 2008 2009 2010 2010 2010 2010 2010 2010 2010	
Lee et al <sup>15</sup> Ryu et al <sup>13</sup> <b>Subtotal (95% CI)</b> Total events Heterogeneity: $r^2=0.6$ Test for overall effect <b>1.1.6 6–24 hours</b> Choi et al <sup>21</sup> Kim et al <sup>20</sup> Hahm et al <sup>18</sup> Kaja et al <sup>14</sup> <b>Subtotal (95% CI)</b> Total events Heterogeneity: $r^2=0.6$ Test for overall effect <b>1.1.7 24–48 hours</b> Choi et al <sup>21</sup> Ryu et al <sup>19</sup> Ansari et al <sup>17</sup> Hahm et al <sup>18</sup> Choi et al <sup>16</sup> Lee et al <sup>15</sup> Ryu et al <sup>19</sup> <b>Subtotal (95% CI)</b> Total events	12 3 19 80; $\chi^2=8.3$ : $Z=1.28$ ( $\ell$ 25 22 16 0 63 009; $\chi^2=6.7$ : $Z=0.59$ ( $\ell$ 12 0 7 21 29 1 4 74 27; $\chi^2=19.2$	60 41 141 3, df=2 (P=( P=0.20) 47 54 42 30 173 0, df=3 (P=( P=0.56) 47 40 65 42 68 60 42 364 23, df=6 (P=	10 17 37 0.02); l <sup>2</sup> =76 25 17 28 1 71 0.08); l <sup>2</sup> =55 17 2 8 10 29 20 8 16 107	60 41 141 % 47 54 42 30 173 % 47 40 65 42 71 60 41 366	37.1% 30.8% 100% 36.1% 32.8% 1.7% 100% 18.9% 2.7% 15.6% 22.9% 21.5% 5.2% 13.1%	1.20 (0.56, 2.56) 0.18 (0.06, 0.56) 0.47 (0.15, 1.49) 1.00 (0.68, 1.46) 1.29 (0.78, 2.15) 0.57 (0.37, 0.89) 0.33 (0.01, 7.87) 0.88 (0.58, 1.35) 0.71 (0.38, 1.31) 0.20 (0.01, 4.04) 0.47 (0.20, 1.07) 0.72 (0.50, 1.04) 1.51 (0.95, 2.40) 0.13 (0.02, 0.97) 0.24 (0.09, 0.67)	2011 2014 2008 2009 2010 2010 2010 2010 2010 2010 2010	

Figure 2 Forest plot of relative risk comparing postoperative nausea between ramosetron and ondansetron treatment. Abbreviations: CI, confidence interval; M–H, Mantel–Haenszel test.

48 hours after surgery, although ramosetron had a tendency to be more effective than ondansetron in the 24–48 hours after treatment. During some of the time periods in the 24 hours after surgery, we found a statistically significant difference between ramosetron and ondansetron with regard to prevention of POV (0–6 hours, 0–24 hours, and 6–24 hours). However, we did not find any difference between these two treatments in the 24–48-hour interval after surgery. To explore the cause for the inconsistency between our results and those of Mihara et al with regard to the ability of ramosetron to prevent late POV (24–48 hours), we compared the selected studies and the data extracted for late POV between our meta-analysis and that by Mihara et al. We included two new studies in our analysis<sup>13,17</sup> and excluded a study by Choi et al<sup>23</sup> that had been selected by Mihara et al. The study reported by Choi et al used dexamethasone as an adjunct to ramosetron and ondansetron for the treatment of PONV. Given that all other selected studies

Study or Subgroup	Ramoseti Events	ron (0.3 mg Total	g) Ondans Events	etron (4 mg) Total	Weight	Risk ratio M–H, random, 95% Cl	Year	Risk ratio M–H, random, 95% Cl
.2.1 0–2 hours								
lahm et al18	0	42	0	42		Not estimable	2010	
Ryu et al19	0	40	Ő	40		Not estimable	2010	
.ee et al <sup>15</sup>	1	60	2	60	57.1%	0.50 (0.05, 5.37)	2011	
Ryu et al <sup>13</sup>	1	42	1	41	42.9%	0.98 (0.06, 15.09)	2011	
Subtotal (95% CI)	1	184	1	183	100%	0.67 (0.11, 4.00)	2014	
otal events	2		3			,		
Heterogeneity: $\tau^2=0.1$ Test for overall effect	00; χ²=0.13			<b>)</b>				
.2.2 0-6 hours		,						
Choi et al <sup>21</sup>	2	47	9	47	21.1%	0.22 (0.05, 0.97)	2008	
Kim et al <sup>20</sup>	4	54	8	54	35.6%	0.50 (0.16, 1.56)	2009	
lahm et al <sup>18</sup>	5	42	8	42	43.3%	0.63 (0.22, 1.75)	2010	
Subtotal (95% CI)		143		143	100%	0.46 (0.24, 0.92)		$\overline{\bullet}$
otal events	11		25					-
leterogeneity: $\tau^2=0.1$ lest for overall effect	00; χ²=1.31			)				
.2.3 2–6 hours								
lahm et al <sup>18</sup>	5	42	8	42	89.4%	0.63 (0.22, 1.75)	2010	
(aja et al <sup>14</sup>	0	30	2	30	10.6%	0.20 (0.01, 4.00)	2014 —	
Subtotal (95% CI)	_	72		72	100%	0.55 (0.21, 1.47)		
otal events leterogeneity: τ <sup>2</sup> =0.			10 .48); /²=0%	)				
est for overall effect .2.4 0–24 hours	. 2-1.19 (F	-0.24)						
(im et al <sup>20</sup>	9	54	11	54	16.4%	0.82 (0.37, 1.81)	2009	
Ryu et al <sup>19</sup>	ŏ	40	0	40	10.170	Not estimable	2010	-
lahm et al18	5	42	13	42	11.8%	0.38 (0.15, 0.98)	2010	<b>_</b>
Choi et al16	12	68	18	71	24.6%	0.70 (0.36, 1.33)	2010	<b>e</b> -+
nsari et al17	20	65	23	65	43.3%	0.87 (0.53, 1.42)	2010	
ee et al <sup>15</sup>	2	60	4	60	3.8%	0.50 (0.10, 2.63)	2011	
Subtotal (95% CI)		329		332	100%	0.72 (0.52, 1.00)		$\bullet$
otal events	48		69					
leterogeneity: $\tau^2=0.1$ Test for overall effect			.63); /²=0%	)				
.2.5 2–24 hours								
Ryu et al19	0	40	0	40		Not estimable	2010	
ee et al15	1	60	2	60	29.7%	0.50 (0.05, 5.37)	2011	
Ryu et al13	2	42	6	41	70.3%	0.33 (0.07, 1.52)	2014	
Subtotal (95% CI)		142		141	100%	0.37 (0.10, 1.35)		
otal events leterogeneity: τ²=0. est for overall effect			8 .77); /²=0%	)				
.2.6 6-24 hours		,						
Choi et al <sup>21</sup>	5	47	11	47	26.2%	0.45 (0.17, 1.21)	2008	<b>_</b> _
Cim et al <sup>20</sup>	7	54	8	54	28.2%	0.88 (0.34, 2.24)	2009	<b>_</b>
lahm et al <sup>18</sup>	7	42	18	42	43.1%	0.39 (0.18, 0.83)	2010	
(aja et al <sup>14</sup>	0	30	1	30	2.5%	0.33 (0.01, 7.87)	2014 —	
Subtotal (95% CI)		173		173	100%	0.51 (0.31, 0.84)		•
otal events leterogeneity: τ²=0. est for overall effect			38 0.60); /²=0%	)				
.2.7 24–48 hours		5.000)						
Choi et al <sup>21</sup>	1	47	1	47	10.8%	1 00 (0 06 15 52)	2008	
	-		-			1.00 (0.06, 15.52)		
Choi et al <sup>16</sup> Ansari et al <sup>17</sup>	8 5	68 65	3 23	71 65	23.4% 28.0%	2.78 (0.77, 10.06) 0.22 (0.09, 0.54)	2010 2010	
lahm et al <sup>18</sup>	5	42	13	42	27.6%	0.38 (0.15, 0.98)	2010	
Ryu et al <sup>19</sup>	Ő	40	0	40	21.070	Not estimable	2010	-
.ee et al <sup>15</sup>	0 0	60	Õ	60		Not estimable	2011	
Ryu et al <sup>13</sup>	0	42	4	41	10.1%	0.11 (0.01, 1.95)	2014 +	
Subtotal (95% CI)	-	364		366	100%	0.51 (0.17, 1.51)		
otal events	19	504	44	500	100/0			
Heterogeneity: $\tau^2=0.1$ Test for overall effect	89; χ²=11.58			5%				
		J/						
							0.01	0.1 1 10

Figure 3 Forest plot of relative risk comparing postoperative vomiting between ramosetron and ondansetron treatment. Abbreviations: CI, confidence interval; M–H, Mantel–Haenszel test.

used only ramosetron or ondansetron, it was inappropriate to include a study with a different regimen. We also found a data extraction error in the meta-analysis by Mihara et al ie, in one selected study,<sup>16</sup> late POV events in the ondansetron group were actually fewer than in the ramosetron group, according to line graph in the original study; however, in the publication by Mihara et al POV events in the ondansetron group were reported to be more common than in the ramosetron group (17 versus nine, respectively).

When comparing the total number of side effects including headache, dizziness, and drowsiness, ramosetron caused

Study or				etron (4 mg)	Weight	Risk ratio	Year	Risk ratio	
subgroup	Events	Total	Events	Iotai		M–H, fixed, 95% C	·I	M–H, fixed	, 95% CI
Choi et al <sup>21</sup>	14	47	27	47	42.1%	0.52 (0.31, 0.86)	2008		
Ansari et al17	8	65	11	65	17.1%	0.73 (0.31, 1.69)	2010		
Lee et al <sup>15</sup>	11	60	13	60	20.3%	0.85 (0.41, 1.74)	2011		-
Ryu et al <sup>13</sup>	9	42	13	41	20.5%	0.68 (0.32, 1.41)	2014		
Subtotal (95% CI)		214		213	100%	0.65 (0.47, 0.91)		•	
Total events 42 Heterogeneity: $\chi^2$ =1.38, <i>df</i> =3 ( <i>P</i> =0.71); <i>l</i> <sup>2</sup> =0% Test for overall effect: <i>Z</i> =2.52 ( <i>P</i> =0.01)			64				0.01 Fave	0.1 1 ors (ramosetron)	10 100 Favors (ondansetron)

Figure 4 Forest plot of relative risk comparing side effects between ramosetron and ondansetron treatment. Abbreviations: CI, confidence interval; M–H, Mantel–Haenszel test.

fewer recorded side effects than ondansetron in the 48 hours after surgery. In view of the US Food and Drug Administration warnings regarding the use of ondansetron in patients with a prolonged QT interval,<sup>24</sup> improved safety would be a good reason to replace ondansetron with ramosetron, even though there was no significant difference in efficacy between these two treatments.

Our meta-analysis has some limitations. The total number of patients analyzed was only 898, with PON and POV events recorded at different time periods in the different studies, so the sample size for each time period was very small. Further, ramosetron is only licensed in Asian countries, with the selected studies all being conducted in Asian population, and it is unclear whether our conclusion is applicable to other populations. Finally, we detected some publication bias in the data on PON and POV events during some time periods in the 24 hours following surgery. Therefore, results for those time periods may not be accurate.

In summary, our current meta-analysis demonstrates that ramosetron was much more effective than ondansetron in the prevention of early POV (0–24 hours) and was associated with fewer side effects. However, our study did not identify any statistically significant differences in efficacy between ramosetron and ondansetron in the prevention of PON and late POV (24–48 hours).




Figure 5 Funnel plot for the assessment of publication bias Abbreviations: RR, relative risk; SE, standard error.

# Disclosure

The authors report no conflicts of interest in this work.

#### References

- Franck M, Radtke FM, Apfel CC, et al. Documentation of postoperative nausea and vomiting in routine clinical practice. *J Int Med Res.* 2010;38:1034–1041.
- Apfel CC, Heidrich FM, Jukar-Rao S, et al. Evidence-based analysis of risk factors for post-operative nausea and vomiting. *Br J Anaesth*. 2012;109:742–753.
- Horn CC, Wallisch WJ, Homanics GE, Williams JP. Pathophysiological and neurochemical mechanisms of postoperative nausea and vomiting. *Eur J Pharmacol*. 2014;722:55–66.
- Habib AS, Chen YT, Taguchi A, Hu XH, Gan TJ. Postoperative nausea and vomiting following inpatient surgeries in a teaching hospital: a retrospective database analysis. *Curr Med Res Opin.* 2006;22:1093–1099.
- Moon YE. Postoperative nausea and vomiting. *Korean J Anesthesiol*. 2014;67:164–170.
- Cox F. Systematic review of ondansetron for the prevention and treatment of postoperative nausea and vomiting in adults. *Br J Theatre Nurs*. 1999;9:556–563.
- Doggrell SA, Hancox JC. Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia. *Expert Opin Drug Saf.* 2013;12:421–431.
- Rabasseda X. Ramosetron, a 5-HT3 receptor antagonist for the control of nausea and vomiting. *Drugs Today (Barc)*. 2002;38:75–89.
- Kim WO, Koo BN, Kim YK, Kil HK. Ramosetron for the prevention of postoperative nausea and vomiting (PONV): a meta-analysis. *Korean J Anesthesiol*. 2011;61:405–412.
- Mihara T, Tojo K, Uchimoto K, Morita S, Goto T. Reevaluation of the effectiveness of ramosetron for preventing postoperative nausea and vomiting: a systematic review and meta-analysis. *Anesth Analg.* 2013; 117:329–339.
- 11. Carlisle JB. A meta-analysis of prevention of postoperative nausea and vomiting: randomised controlled trials by Fujii et al compared with other authors. *Anaesthesia*. 2012;67:1076–1090.
- 12. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? *Control Clin Trials*. 1996;17:1–12.
- Ryu JH, Lee JE, Lim YJ, et al. A prospective, randomized, double-blind, and multicenter trial of prophylactic effects of ramosetron on postoperative nausea and vomiting (PONV) after craniotomy: comparison with ondansetron. *BMC Anesthesiol*. 2014;14:63.

- Kaja S, Giri RS, Tugave DV, Iqbal M. A randomized clinical trial comparing the efficacy and safety of ramosetron versus ondansetron in patients undergoing abdominal surgery under general anesthesia. *Saudi J Anaesth.* 2014;8:59–63.
- Lee JW, Park HJ, Choi J, Park SJ, Kang H, Kim EG. Comparison of ramosetron's and ondansetron's preventive anti-emetic effects in highly susceptible patients undergoing abdominal hysterectomy. *Korean J Anesthesiol*. 2011;61:488–492.
- Choi DK, Chin JH, Lee EH, et al. Prophylactic control of post-operative nausea and vomiting using ondansetron and ramosetron after cardiac surgery. *Acta Anaesthesiol Scand*. 2010;54:962–969.
- Ansari MM, Siddiqui OA, Haleem S, Varshney R, Akhtar S, Khan FA. Comparison of ramosetron and ondansetron for control of post-operative nausea and vomiting following laparoscopic cholecystectomy. *Indian J Med Sci.* 2010;64:272–280.
- Hahm TS, Ko JS, Choi SJ, Gwak MS. Comparison of the prophylactic anti-emetic efficacy of ramosetron and ondansetron in patients at highrisk for postoperative nausea and vomiting after total knee replacement. *Anaesthesia*. 2010;65:500–504.
- Ryu J, So YM, Hwang J, Do SH. Ramosetron versus ondansetron for the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy. *Surg Endosc.* 2010;24:812–817.
- Kim SI, Kim SC, Baek YH, Ok SY, Kim SH. Comparison of ramosetron with ondansetron for prevention of postoperative nausea and vomiting in patients undergoing gynaecological surgery. *Br J Anaesth.* 2009;103: 549–553.
- Choi YS, Shim JK, Yoon DH, Jeon DH, Lee JY, Kwak YL. Effect of ramosetron on patient-controlled analgesia related nausea and vomiting after spine surgery in highly susceptible patients: comparison with ondansetron. *Spine (Phila Pa 1976)*. 2008;33:E602–E606.
- Banerjee D, Das A, Majumdar S, et al. PONV in ambulatory surgery: a comparison between ramosetron and ondansetron: a prospective, double-blinded, and randomized controlled study. *Saudi J Anaesth*. 2014;8:25–29.
- 23. Choi YS, Shim JK, Ahn SH, Kwak YL. Efficacy comparison of ramosetron with ondansetron on preventing nausea and vomiting in high-risk patients following spine surgery with a single bolus of dexamethasone as an adjunct. *Korean J Anesthesiol*. 2012;62:543–547.
- Food and Drug Administration. FDA Drug Safety Communication: Abnormal heart rhythms may be associated with use of Zofran (ondansetron), 2011. Available from: http://www.fda.gov/Drugs/DrugSafety/ ucm271913.htm. Accessed March 18, 2015.

#### Drug Design, Development and Therapy

#### Publish your work in this journal

Drug Design, Development and Therapy is an international, peerreviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: http://www.dovepress.com/drug-design-development-and-therapy-journal

**Dove**press